Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity

Cardiovascular Research

Volumn 97, Issue 1, 2013, Pages 44-54

  Ruggiero, Alessandra ^a   Chen, Suet Nee ^a   Lombardi, Raffaella ^a   Rodriguez, Gabriela ^a   Marian, Ali J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Calcineurin; Genetics; Hypertrophy; Myozenin 2; Sarcomere

Indexed keywords

ALPHA ACTININ; CALCINEURIN; CALCINEURIN INHIBITOR; CALCINEURIN PROTEIN PHOSPHATASE 2B; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOZENIN 2; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; GENE MUTATION; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOFLUORESCENCE; LENTIVIRINAE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CALCINEURIN; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENES, REPORTER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; MUSCLE PROTEINS; MUTATION; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; PHENOTYPE; PHOSPHORYLATION; RATS; RNA, MESSENGER; TRANSFECTION;

EID: 84871761309     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs294     Document Type: Article

References (26)

1. Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic car-diomyopathy: a personal history. Circ Res 2011;108:743-750.
2. Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010;40:360-369.
3. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P et al. Myocar-dial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-563.
4. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119:1085-1092.
5. Wen Y, Pinto JR, Gomes AV, Xu Y, Wang Y, Potter JD et al. Functional consequences of the human cardiac troponin i hypertrophic cardiomyopathy mutation r145g in transgenic mice. J Biol Chem 2008;283:20484-20494.
6. Lowey S, Lesko LM, Rovner AS, Hodges AR, White SL, Low RB et al. Functional effects of the hypertrophic cardiomyopathy r403q mutation are different in an alpha-or beta-myosin heavy chain backbone. J Biol Chem 2008;283:20579-20589.
7. Frey N, Brixius K, Schwinger RH, Benis T, Karpowski A, Lorenzen HP et al. Alterations of tension-dependent atp utilization in a transgenic rat model of hypertrophic cardio-myopathy. J Biol Chem 2006;281:29575-29582. (Pubitemid 44536965)
8. Osio A, Tan L, Chen SN, Lombardi R, Nagueh SF, Shete S et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res 2007;100:766-768. (Pubitemid 46555681)
9. Frey N, Barrientos T, Shelton JM, Frank D, Rutten H, Gehring D et al. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyop-athy in response to pathological biomechanical stress. Nat Med 2004;10:1336-1343. (Pubitemid 40022715)
10. Frey N, Richardson JA, Olson EN. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci USA 2000;97:14632-14637. (Pubitemid 32016627)
11. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93:215-228. (Pubitemid 28180855)
12. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600. (Pubitemid 44325350)
13. Turska-Kmiec A, Jankowska I, Pawlowska J, Kalicinski P, Kawalec W, Tomyn M et al. Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient. Pediatr Transplant 2007;11:319-323. (Pubitemid 46570139)
14. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, Schoen FJ et al. An abnormal ca(2+) response in mutant sarcomere protein-mediated familial hyper-trophic cardiomyopathy. J Clin Invest 2000;106:1351-1359.
15. Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 1991;266:9180-9185. (Pubitemid 21906635)
16. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM et al. Calcineurin/nfat coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110-118. (Pubitemid 38064105)
17. Lombardi R, Bell A, Senthil V, Sidhu J, Noseda M, Roberts R et al. Differential interactions of thin filament proteins in two cardiac troponin t mouse models of hyper-trophic and dilated cardiomyopathies. Cardiovasc Res 2008;79:109-117. (Pubitemid 351881942)
18. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant n-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006;47:827-834. (Pubitemid 43243108)
19. Lombardi R, da Graca Cabreira-Hansen M, Bell A, Fromm RR, Willerson JT, Marian AJ. Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res 2011;109:1342-1353.
20. Chen SN, Czernuszewicz G, Tan Y, Lombardi R, Jin J, Willerson JT et al. Human molecular genetic and functional studies identify trim63, encoding muscle ring finger protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res 2012; 111:907-919.
21. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109:1284-1291. (Pubitemid 38372788)
22. Frank D, Kuhn C, van Eickels M, Gehring D, Hanselmann C, Lippl S et al. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy. Circulation 2007;116:2587-2596. (Pubitemid 350179222)
23. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S et al. Targeted inhibition of p38 mapk promotes hypertrophic cardiomyopathy through upregulation of calcineurin-nfat signaling. J Clin Invest 2003;111:1475-1486. (Pubitemid 38063280)
24. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. C-jun n-terminal kinases (jnk) antagonize cardiac growth through cross-talk with calcineurin-nfat signaling. EMBO J 2003;22:5079-5089. (Pubitemid 37222028)
25. Gautel M. The sarcomere and the nucleus: functional links to hypertrophy, atrophy and sarcopenia. Adv Exp Med Biol 2008;642:176-191.
26. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels vs. demons in a heart-breaking tale. Physiol Rev 2010;90:1507-1546.